The Indian Pharmaceutical Market (IPM) achieved growth of 15.3 per cent to Rs.9,388 crore during November 2016 as against 9.8 per cent in November 2015 due to significant growth in volumes. Average Average Growth for the quarter was at 12.2 per cent against 14.2 per cent in the last year. According to AIOCD-AWACS report, chronic market grew at a very high double digit growth and. Anti-diabetic market grew at 32.6 per cent & cardiac market grew at 20.88 per cent. Without anti-diabetic & cardiac markets the IPM growth would have been 12.6 per cent.
Market has added Rs.1,243 crore over last year, whereas last year the market had added up Rs.727 crore. 34 per cent of the incremental value comes from cardiac & anti-diabetic markets. The November quarter saw a volume growth of 6.9 per cent & price growth the lowest in last 6 quarters at 2.1 per cent which has been consistently falling down on the back of price cuts. Chronic portfolio shows a high volume growth at 15.7 per cent against acute market volume growth of 5.3 per cent for November 2016.
The FDCs related market degrew at 30 per cent whereas the non FDCs market grew at 16.7 per cent. The non FDC market has grown better in this quarter growing at 13.4 per cent. From a GD perspective the FDC containing market showed a huge volume degrowth of 34.4 per cent. Indian companies degrew by 30.8 per cent in the FDC portfolio whereas the MNCs degrew by 27.9 per cent for November month.
For the month of November 2016, amongst the top 10, Intas grew at 22.9 per cent, Sun at 20.1 per cent followed by Abbott at 19.8 per cent. 27 corporate have crossed the growth of IPM amongst top 50. Amongst the top 50 corporate Boehringer Ingelheim has the highest growth of 35.2 per cent followed by AstraZeneca at 34.4 per cent & Eris at 32.9 per cent. 24 corporate showed growths more than 10 per cent amongst the top 50. Abbott HC grew at 11.7 per cent whereas Abbott India grew at 21.6 per cent for the month of November-16. Zuventus grows at 27.4 per cent, Emcure at 16.9 per cent, Novo Nordisk grows at 41.3 per cent. Sun portfolio grew by 23.1 per cent whereas Ranbaxy portfolio grew at 15.1 per cent.
Total 113 companies launched in last 36 months. 6 companies cross Rs.10 crore in revenue. The new companies launched within last 36 months is now being led by Saffron Therapeutics, Brinton Healthcare, Innovcare LifeSciences, Arinna Life Sciences & Jubilant Life Sciences.
Indian companies have grown at 15.1 per cent versus 16.0 per cent for MNCs in November 2016. Amongst the top 50 in MNCs, Boehringer grew at 35.2 per cent followed by AstraZeneca at 34.4 per cent and Allergan at 30.8 per cent. Under the non-NLEM category Indian companies grew at11.0 per cent whereas MNCs grew at -6.4 per cent.
From therapy perspective 10 therapies have outgrown the IPM growth. Respiratory market grew at 8.5 per cent, gastro intestinal market grew at 13.2 per cent, pain & analgesics market grew at 11.5 per cent whereas anti-infectives grew at 1.9 per cent. Anti-diabetic market grows at 32.6 per cent & cardiac at 20.9 per cent, neuro/CNS at 14.6 per cent in chronic business. Anti-malarials degrew at 12.2 per cent, VMS market at 17.5 per cent. Derma market grew by 16.9 per cent & urology Market at 24.5 per cent.
From regional perspective 12 regions have outgrown the IPM growth. Mumbai city market grew the highest at 38.1 per cent followed by Outer Mumbai market at 25.8 per cent & Delhi market at 22.4 per cent. No regions had negative growth in November-16.
Amoxycillin+clavulanic acid market grew at 0.0% & glimepiride +metformin market grew at 39.8 per cent. Glimepiride+metformin was pegged at Rs.171 crore for the month of November 2016, the highest till date. The markets of paracetamol grew at 14.3 per cent, atorvastatin -1.8 per cent, probiotic microbes at 12.4 per cent, bacillus clausii market at 16.3 per cent, cefixime at -3.3 per cent, pantoprazole at 15.4 per cent, montelukast+levocetrizine at 23.7 per cent, glimepiride+metformin+pioglitazone at -15.8 per cent, vitamin-D at 9.2 per cent, hydroquinone +mometasone +tretinoin at 1.0 per cent, voglibose +metformin +glimepiride at 59.2%, rosuvastatin at 37.2%, protein supplements at 36.2%, azithromycin at -8.2%, calcium carbonate + Vit D3 market at 26.2%, paracetamol + phenylephrine + chlorpheniramine at 10.1%, meropenem at 37.1%, montelukast + fexofenadine at 23.4%, diclofenac at 14.6%, telmisartan at 5.9%, levetiracetam at 15.8%, cefpodoxime at 8.3%, ranitidine at 8.9%.
Mixtard leads the pack with Rs.49 crore followed by Spasmoproxyvon Plus at Rs.40 crore, Glycomet GP at Rs.37 crore, Lantus Rs.34 crore, Galvusmet at Rs.34 crore and Janumet at Rs.30 crore for November 2016. Few brands who have gained ranks include Hepcinat L (+33122), Bortenat (+147), Amaryl M (+57), Meronem (+45), Duolin (+41), Revital H (+34), Ecosprin AV (+33), Istamet (+31) and Chymoral Forte (+30). 100th Biggest Brand in IPM is Deriphyllin from Zydus & 300th Biggest Brand is Neo Mercazole from Abbott Healthcare on MAT basis
Total 177 brands & 317 SKUs launched in November 2016. Top 5 new brands for November 2016 are Zuvendine, Codylex T, Emluz, Cialis, Ulitas. Zuventus enters the Sofosbuvir combination market by launching Lesovir in the sofosbuvir+ledipasavir market. Biggest launch by MNCs – Tossex XP from Abbott. New subgroup launched in November is codeine +triprolidine. Within the antidiabetic category Eglucent (Lupin), Teneliglip M (Akumentis), Tenefit M (Systopic), Tenipack M (Koye).